Diligence memo · auto-generated · as of July 2, 2026
Aspicio Therapeutics, Inc.
Aspicio Therapeutics, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Aspicio Therapeutics, Inc. operates in Pharma, based in DOWNINGTON.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Aspicio Therapeutics, Inc. has raised $400K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $400K on 2024-06-18.
Most recent recorded round closed around 2024-06-18.
Valuation (modeled)modeled
Provath models Aspicio Therapeutics, Inc. at approximately $1.9M (range $224K–$6.3M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.78× the median modeled value of Pre-Seed Pharma companies in 2022–2024 (15 peers) — value vs value, same stage and era. Within the normal band (78% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.0 yr ago; this sector typically re-raises about every 16 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 26% of Pharma peers (310 compared).
Modeled value ranks above 22% of those peers.
Closest niche peers: Acanna Therapeutics, Inc., Neural Therapeutics Inc., Insignis Therapeutics Inc., Atacama Therapeutics, Inc., Pharma Acuity, Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.